GlobeNewswire by notified

TJP Labs Inc. Amends Its Drug Establishment License and Achieves Approval for Active Pharmaceutical Ingredients

Share

PICKERING, Ontario, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TJP Labs Inc. ("TJP Labs") is North America's leading full-service contract manufacturer of premier next-generation products, focusing on modern oral nicotine pouches and oral delivery solutions for caffeine and other nutraceutical products. Today, TJP Labs announced that after completing a thorough regulatory assessment and meeting all GMP requirements, it received a notice of compliance for Active Pharmaceutical Ingredients (API) following an audit by the Health Canada Drug GMP Inspection Program.

The announcement aligns with TJP Labs' strategy to offer drug manufacturing services, and the new achievement enables TJP Labs to spearhead further licensable activities. 

Speaking on the achievement, David Richmond-Peck, CEO of TJP Labs, remarked: 

"I cannot overstate the significance of this most recent compliant rating by Health Canada, and I congratulate our quality and manufacturing teams on their continued success. 

GMP certification for Active Pharmaceutical Ingredients accelerates TJP's bold innovation strategy in the modern oral and beyond nicotine categories. Furthermore, it reinforces that our facilities operate to a set of internationally recognized pharmaceutical standards to ensure product quality and safety. 

The modern oral category is seeing exponential growth and this critical API milestone positions TJP as a formidable and aggressive partner. There is a growing demand for innovation, and our certifications give us the unique ability to provide more value-added products and services. But, most importantly, it allows us to offer a broad range of best-in-class products across multiple categories. It also enhances TJP's long-term value for our investors."

About TJP Labs Inc. 
TJP Labs is a leading North American full-service manufacturer of premium quality next-generation products, specializing in modern oral nicotine, energy, and nutraceutical pouches. Our products are manufactured and packaged in our DEL, Site-Licensed, cGMP/HACCP compliant, ISO 9001:2015 certified state-of-the-art facilities.

Contacts

David Richmond-Peck - business@tjplabs.com

Website: www.tjplabs.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Summary Notice of Pendency and Proposed Settlement of Shareholder Derivative Actions3.5.2024 22:39:16 CEST | Press release

CUPERTINO, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Apple Inc. has released the following notice: A Federal Court authorized this Notice. This is not a solicitation from a lawyer. TO: ALL PERSONS OR ENTITIES WHO OR WHICH HELD SHARES OF APPLE INC. (“APPLE” OR THE “COMPANY”) COMMON STOCK AS OF THE CLOSE OF TRADING ON APRIL 29, 2024. THIS NOTICE RELATES TO THE PENDENCY AND PROPOSED SETTLEMENT OF SHAREHOLDER DERIVATIVE LITIGATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IF YOU ARE A CURRENT APPLE SHAREHOLDER, THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT YOUR RIGHTS. THIS ACTION IS NOT A “CLASS ACTION.” THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR MONETARY PAYMENT. IF YOU DO NOT OBJECT TO THE TERMS OF THE PROPOSED SETTLEMENT OR THE AMOUNT OF ATTORNEYS’ FEES AND EXPENSES DESCRIBED IN THIS NOTICE, YOU ARE NOT OBLIGATED TO TAKE ANY ACTION. The purpose of this Notice is to inform you of: (i) the pendency of the shareholder derivative action brought on beh

CNH announces voting results of 2024 Annual General Meeting and publishes 2023 Sustainability Report3.5.2024 22:30:00 CEST | Press release

Basildon, May 3, 2024 CNH Industrial N.V. (NYSE: CNHI) today held its annual general meeting of shareholders. Shareholders re-appointed the Company’s director nominees, including Suzanne Heywood and Scott W. Wine as executive directors1, and Elizabeth Bastoni, Howard W. Buffett, Richard J. Kramer, Karen Linehan, Alessandro Nasi, Vagn Sørensen and Åsa Tamsons as non-executive directors. Shareholders also approved a dividend of $0.47 per common share (equivalent to a total distribution of approximately $585 million), and the AGM approved the Company’s Remuneration Policy. In other voting, shareholders appointed Deloitte Accountants B.V. as the independent auditor for the 2025 financial year and approved the Company’s 2023 financial statements prepared under IFRS. Details of all matters approved today by the AGM are available on the Company's website (www.cnh.com). *** The dividend is payable on May 29, 2024 to shareholders of record on May 13, 2024. Shareholders holding CNH common shares

Nokia Corporation: Repurchase of own shares on 03.05.20243.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 03 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 03.05.2024 Espoo, Finland – On 03 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL379,8083.44CEUX--BATE--AQEU--TQEX--Total379,8083.44 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons3.5.2024 19:48:16 CEST | Press release

Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar2 Reason for the notificationa)Position/statusExecutive Vice Presidentb)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN342

Subsea 7 S.A. notification of major holding3.5.2024 18:32:01 CEST | Press release

Luxembourg –3 May 2024 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced that, on 3 May 2024, Barclays Capital Securities Limited1 informed the Company that it had breached thresholds provided for by Luxembourg’s Transparency Law of 11 January 2008 on transparency requirements for issuers of securities as amended (the “Transparency Law”) as follows: On 30 April 2024 the total number of voting rights in the Company according to Article 8 and 9 of the Transparency Law attached to shares was 1,044,272 On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (a) of the Transparency Law (right to recall) was 13,906,019On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (b) of the Transparency Law (swaps) was 499,740 When combined, the above positions equate to 5.07% of voting r

HiddenA line styled icon from Orion Icon Library.Eye